author-photo

Sunil S. Patel

University of Southern California

36

Papers

2434

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

2021
Show All
- Source
- Cite
- Save
Citations (0)
PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.

2020 Retina-the Journal of Retinal and Vitreous Diseases
Show All
- Source
- Cite
- Save
Citations (18)
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.

2020 JAMA Ophthalmology
Show All
- Source
- Cite
- Save
Citations (43)
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.

2020 JAMA Ophthalmology
Show All
- Source
- Cite
- Save
Citations (22)
Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability

2019 Investigative Ophthalmology & Visual Science
Show All
- Source
- Cite
- Save
Citations (6)
Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

2019
Show All
- Source
- Cite
- Save
Citations (6)
Intravitreal Combined Aflibercept + Anti–Platelet-Derived Growth Factor Receptor β for nAMD: Results of the Phase 2 CAPELLA Trial

2019 Ophthalmology
Show All
- Source
- Cite
- Save
Citations (7)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

2019 Ophthalmology
Show All
- Source
- Cite
- Save
Citations (75)
Anti-VEGF/anti-angiopoietin-2 bispecific antibody RG7716 in diabetic macular edema: complete 36-week results from the phase 2, multicenter, randomized, active treatment-controlled BOULEVARD clinical trial

2018 Investigative Ophthalmology & Visual Science
Show All
- Source
- Cite
- Save
Citations (0)
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.

2018 Journal of Ocular Pharmacology and Therapeutics
Show All
- Source
- Cite
- Save
Citations (4)